DwightDBlakeMD

Internal Medicine • Union City, GA

Internal medicine at Rophe Adult & Pediatric Medicine

Join to view full profile

Dr. Blake is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Blake's full profile

Already have an account?

Office
4910 Jonesboro Rd
Bldg. 700, Ste. 1
Union City, GA 30291
Phone+1 770-964-7736

Fax+1 770-306-1726

Education & Training

University of Miami/Jackson Health SystemResidency, Internal Medicine, 1984 - 1987
State University of New York Downstate Medical Center College of MedicineClass of 1984

Certifications & Licensure

GA State Medical License 2002 - 2025
FL State Medical License 1986 - 2005

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2020 Jul 01
Completed
Phase 2
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3) Start of enrollment: 2021 Aug 27
Recruiting
Phase 3
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time Start of enrollment: 2022 Jun 03
Completed
Phase 3
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss Start of enrollment: 2021 Mar 29
Completed
Phase 3
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone Start of enrollment: 2019 Jun 03
Completed
Phase 3
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity Start of enrollment: 2022 Oct 11
Active, not recruiting
Phase 3
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease Start of enrollment: 2022 Mar 07
Recruiting
Phase 2, Phase 3
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older Start of enrollment: 2022 Sep 12
Completed
Phase 3
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin Start of enrollment: 2022 Mar 08
Completed
Phase 3
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode Start of enrollment: 2019 Oct 08
Active, not recruiting
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk Start of enrollment: 2023 Apr 03
Recruiting
Phase 3
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes Start of enrollment: 2019 Apr 01
Completed
Phase 3
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes Start of enrollment: 2019 Jul 30
Completed
Phase 3
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children Start of enrollment: 2022 Sep 23
Recruiting
Phase 2, Phase 3
An Efficacy and Safety Study w/ Azstarys® in Children With ADHD Start of enrollment: 2023 Mar 22
Active, not recruiting
Phase 4
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities Start of enrollment: 2023 Apr 21
Active, not recruiting
Phase 3
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight Start of enrollment: 2019 Dec 04
Active, not recruiting
Phase 3
Join now to see all